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Prophylactic Antiepileptic Treatment in Tuberous Sclerosis 
 
Jóźwiak et al.1 suggest that their study, “...provides evidence that preventive antiepileptic 
treatment in infants with tuberous sclerosis complex improves long-term epilepsy control 
and cognitive outcome at school age.” The study is problematic, however, because it 
compares two groups that have been ascertained in entirely different ways: the “Standard” 
group after presentation with TSC and usually epilepsy; and the “Preventive” group with 
suspected or proven TSC but without epilepsy.  
In the Preventive group, 11 infants received antiepileptic treatment in anticipation of any 
seizures, and four in that group did not develop seizures. Three infants in that group did 
not receive preventive treatment, but neither did they develop seizures. One could argue 
that they were managed in the standard fashion and that their IQs should have been 
analyzed as part of the outcomes in the Standard group. Instead, the authors have 
adopted an implicit intention-to-treat analysis in a situation where the study is descriptive 
and there has been no element of randomization.  
The fact that one-fifth of those cases did not develop epilepsy despite failing to receive the 
preventive treatment highlights the likelihood of there being a significant ascertainment 
bias at play. The likely impact of such bias or misclassification is illustrated by the relative 
paucity of observations in the Preventive group (see figure 1).  
Table 3 of the study presented both median and mean IQs for these groups, but the P-
values do not seem to be derived from the nonparametric statistical tests promised in the 
Methods section. Based on the IQ data from tables 1 and 2, for example, a two-sample 
Wilcoxon rank-sum test on the main IQ analysis gives P=0.046 (z=1.997). And the same 
test performed after moving the IQ result for case 14, which had not received preventive 
treatment, to the Standard group gives P=0.081 (z=1.747). Therefore, even if the 
appropriate independence and distributional assumptions had been valid, a sensitivity 
analysis shows the result to be at best of borderline statistical significance.  
Finally, there is a question of the biological plausibility of the findings. We are excited by 
the idea of identifying a preventive strategy that will help to improve such outcomes, but 
most clinicians will find it hard to believe that this intervention resulted in an improvement 
in median IQ of 48 points.  







Figure 1: Distribution of IQ at last assessment in Standard and Preventive groups.  
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